COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,046 Articles (22,627 medRxiv, 8,419 bioRxiv)

Most recent first Previous |  Page 1441: Articles 14401-14410  | Next

The potential of SARS-CoV-2 antigen-detection tests in the screening of asymptomatic persons
Wachinger, J., Olaru, I. D., Horner, S., Schnitzler, P., Heeg, K., Denkinger, C.
10.1101/2021.06.07.21258465 — Posted: 2021-06-10
BNT162b2 mRNA vaccinations in Israel: understanding the impact and improving the vaccination policies by redefining the immunized population
ross, c., spector, o., Tsadok, M. A., Weiss, Y., Barnea, R.
10.1101/2021.06.08.21258471 — Posted: 2021-06-10
An outbreak of SARS-CoV-2 with high mortality in mink (Neovison vison) on multiple Utah farms
Eckstrand, C., Baldwin, T., Torchetti, M. K., Killian, M. L., Rood, K. A., Clayton, M., Lott, J. A., Wolking, R. M., Bradway, D. S., Baszler, T.
10.1101/2021.06.09.447754 — Posted: 2021-06-10
Analysis of cell-mediated immunity in people with long Covid.
Montes, N., Domenech, E., Guerrero, S., Oliván-Blázquez, B., Magallon-Botalla, R.
10.1101/2021.06.09.21258553 — Posted: 2021-06-09
Second Generation Antibodies Neutralize Emerging SARS-CoV-2 Variants of Concern
Kovacech, B., Fialova, L., Filipcik, P., Zilkova, M., Skrabana, R., Paulenka-Ivanovova, N., Kovac, A., Palova, D., Paulikova Rolkova, G., Tomkova, K., Turic Csokova, N., Markova, K., Skrabanova, M., Sinska, K., Basheer, N., Majerova, P., Hanes, J., Parrak, V., Prcina, M., Cehlar, O., Cente, M., Piestansky, J., Fresser, M., Novak, M., Slavikova, M., Borsova, K., Cabanova, V., Brejova, B., Vinar, T., Nosek, J., Klempa, B., Zilka, N., Kontsekova, E.
10.1101/2021.06.09.447527 — Posted: 2021-06-09
SARS-CoV-2 B.1.617 Indian variants: are electrostatic potential changes responsible for a higher transmission rate?
Pascarella, S., Ciccozzi, M., Zella, D., Bianchi, M., Benedetti, F., Broccolo, F., Cauda, R., Caruso, A., Angeletti, S., Giovanetti, M., Cassone, A.
10.1101/2021.06.08.445535 — Posted: 2021-06-09
Country-wide genomic surveillance of SARS-CoV-2 strains
Kalia, K., Saberwal, G., Sharma, G.
10.1101/2021.06.08.447365 — Posted: 2021-06-09 Discussion: Onsite
Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant.
Moore, P., Moyo, T., Hermanus, T., Kgagudi, P., Ayres, F., Makhado, Z., Sadoff, J., Le Gars, M., van Roey, G., Crowther, C., Garrett, N., Bekker, L.-G., Morris, L., Schuitemaker, H., Gray, G.
10.1101/2021.06.09.447722 — Posted: 2021-06-09
Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine
Pitcovski, J., Gruzdev, N., Abzach, A., Katz, C., Ben-Adiva, R., Brand Schwartz, M., Yadid, I., Haviv, H., Rapoport, I., Bloch, I., Shadmon, R., Eitan, Z., Eliyahu, D., Hillel, T., Laster, M., Kremer Tal, S., Byk Tennenbaum, T., Shahar, E.
10.1101/2021.06.09.447656 — Posted: 2021-06-09
DNA damage response at telomeres boosts the transcription of SARS-CoV-2 receptor ACE2 during aging
Sepe, S., Rossiello, F., Cancila, V., Iannelli, F., Matti, V., Cicio, G., Cabrini, M., Marinelli, E., Alabi, B., di Lillo, A., Di Napoli, A., Shay, J. W., Tripodo, C., d'Adda di Fagagna, F.
10.1101/2021.06.09.447484 — Posted: 2021-06-09 Discussion: Onsite | Offsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).